CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Tricholoacetic Acid (TCA)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02905903
NCT02905903N/ACompleted
CompareCT.gov

An In Vivo Model for Postinflammatory Hyperpigmentation: Part II

Henry Ford Health System·interventional·Posted Sep 19, 2016·Updated Mar 2, 2022

In Brief

A clinical study evaluating Tricholoacetic Acid (TCA) for Post-inflammatory Hyperpigmentation. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the treatment of PIH. In this second phase of the study, the investigators would like to determine if a lower concentration of TCA-induced PIH is comparable to acne-induced PIH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-inflammatory Hyperpigmentation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 19, 2016
Enrollment StartFeb 14, 2016
Primary CompletionMay 16, 2018
Study CompletionJun 21, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.8 years ago

Interventions

Tricholoacetic Acid (TCA)drug

We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.